Skip to main content
TipRanks
Go Ultimate75% OFF

John Michael Maslowski Insider Profile

4 Followers

John Michael Maslowski, former CEO, Director at Fibrocell Science, holds 0.00 shares in Fibrocell Science (Ticker: FCSC).

John Michael Maslowski's Trading History

FCSC
Fibrocell Science
Dec 13, 2019―Uninformative Sell9.49K$0.00
FCSC
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Dec 13, 2019Uninformative Sell$9.49K3,164$3.00―
Aug 23, 2018Informative Buy$6.18K3,000$2.06-5.50%
Aug 11, 2015Informative Buy$6.33K1,000$6.33-82.30%
Nov 21, 2014Informative Buy$2.54K1,000$2.54+106.80%
May 23, 2014Uninformative Buy―480$42.30―

You May Also Like

John Michael Maslowski insider profile FAQ

What is the percentage of profitable transactions made by John Michael Maslowski?
The percentage of profitable transactions made by John Michael Maslowski is 33%.
What is the average return per transaction made by John Michael Maslowski?
The average return per transaction made by John Michael Maslowski is 6.30%.
What stocks does John Michael Maslowski hold?
John Michael Maslowski holds: FCSC stocks.
What was John Michael Maslowski’s latest transaction?
John Michael Maslowski’s latest transaction was an Uninformative Sell of $9.49K.
What was John Michael Maslowski's most profitable transaction?
John Michael Maslowski’s most profitable transaction was an Informative Buy of FCSC stock on November 21, 2014. The return on the trade was 106.80%.
What is John Michael Maslowski's role in Fibrocell Science?
John Michael Maslowski's role in Fibrocell Science is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.